Antiviral Drugs Specific for Coronaviruses in Preclinical Development
Identifieur interne : 000A47 ( Main/Exploration ); précédent : 000A46; suivant : 000A48Antiviral Drugs Specific for Coronaviruses in Preclinical Development
Auteurs : Adeyemi O. Adedeji [États-Unis] ; Stefan G. Sarafianos [États-Unis]Source :
- Current opinion in virology [ 1879-6257 ] ; 2014.
Abstract
Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics.
Url:
DOI: 10.1016/j.coviro.2014.06.002
PubMed: 24997250
PubMed Central: 4195804
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000509
- to stream Pmc, to step Curation: 000509
- to stream Pmc, to step Checkpoint: 000425
- to stream Ncbi, to step Merge: 000396
- to stream Ncbi, to step Curation: 000396
- to stream Ncbi, to step Checkpoint: 000396
- to stream Main, to step Merge: 000A49
- to stream Main, to step Curation: 000A47
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral Drugs Specific for Coronaviruses in Preclinical Development</title><author><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O." last="Adedeji">Adeyemi O. Adedeji</name><affiliation wicri:level="2"><nlm:aff id="A1">Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis</wicri:cityArea></affiliation></author><author><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G." last="Sarafianos">Stefan G. Sarafianos</name><affiliation wicri:level="2"><nlm:aff id="A2">Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>Christopher Bond Life Sciences Center, University of Missouri, Columbia</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="A3">Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, MO 65211</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="A4">Department of Biochemistry, University of Missouri, Columbia, MO 65211</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>Department of Biochemistry, University of Missouri, Columbia</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24997250</idno><idno type="pmc">4195804</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195804</idno><idno type="RBID">PMC:4195804</idno><idno type="doi">10.1016/j.coviro.2014.06.002</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000509</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000509</idno><idno type="wicri:Area/Pmc/Curation">000509</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000509</idno><idno type="wicri:Area/Pmc/Checkpoint">000425</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000425</idno><idno type="wicri:Area/Ncbi/Merge">000396</idno><idno type="wicri:Area/Ncbi/Curation">000396</idno><idno type="wicri:Area/Ncbi/Checkpoint">000396</idno><idno type="wicri:doubleKey">1879-6257:2014:Adedeji A:antiviral:drugs:specific</idno><idno type="wicri:Area/Main/Merge">000A49</idno><idno type="wicri:Area/Main/Curation">000A47</idno><idno type="wicri:Area/Main/Exploration">000A47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Antiviral Drugs Specific for Coronaviruses in Preclinical Development</title><author><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O." last="Adedeji">Adeyemi O. Adedeji</name><affiliation wicri:level="2"><nlm:aff id="A1">Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis</wicri:cityArea></affiliation></author><author><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G." last="Sarafianos">Stefan G. Sarafianos</name><affiliation wicri:level="2"><nlm:aff id="A2">Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>Christopher Bond Life Sciences Center, University of Missouri, Columbia</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="A3">Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, MO 65211</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="A4">Department of Biochemistry, University of Missouri, Columbia, MO 65211</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>Department of Biochemistry, University of Missouri, Columbia</wicri:cityArea></affiliation></author></analytic><series><title level="j">Current opinion in virology</title><idno type="ISSN">1879-6257</idno><idno type="eISSN">1879-6265</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics.</p></div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Missouri (État)</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O." last="Adedeji">Adeyemi O. Adedeji</name></region><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G." last="Sarafianos">Stefan G. Sarafianos</name><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G." last="Sarafianos">Stefan G. Sarafianos</name><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G." last="Sarafianos">Stefan G. Sarafianos</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4195804
|texte= Antiviral Drugs Specific for Coronaviruses in Preclinical Development
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24997250" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |